GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (CHIX:NYXHb) » Definitions » EBITDA Margin %

Nyxoah (CHIX:NYXHB) EBITDA Margin % : -886.73% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nyxoah EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nyxoah's EBITDA for the three months ended in Mar. 2024 was €-10.83 Mil. Nyxoah's Revenue for the three months ended in Mar. 2024 was €1.22 Mil. Therefore, Nyxoah's EBITDA margin for the quarter that ended in Mar. 2024 was -886.73%.


Nyxoah EBITDA Margin % Historical Data

The historical data trend for Nyxoah's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah EBITDA Margin % Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - -16,426.09 -2,651.53 -904.25 -967.80

Nyxoah Quarterly Data
Dec17 Dec18 Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,464.63 -1,016.89 -948.46 -572.81 -886.73

Competitive Comparison of Nyxoah's EBITDA Margin %

For the Medical Instruments & Supplies subindustry, Nyxoah's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nyxoah's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nyxoah's EBITDA Margin % falls into.



Nyxoah EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nyxoah's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-42.08/4.348
=-967.80 %

Nyxoah's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-10.827/1.221
=-886.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyxoah  (CHIX:NYXHb) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Nyxoah EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nyxoah's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyxoah (CHIX:NYXHB) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Nyxoah (CHIX:NYXHB) Headlines

No Headlines